Spinal Drop Metastasis in Myxopapillary Ependymoma: A Case Report and a Review of Treatment Options
Author(s) -
James E. Bates,
Carl R. Peterson,
Gabrielle Yeaney,
Kevin A. Walter,
Thomas Lundquist,
D. Rosenzweig,
Michael T. Milano
Publication year - 2014
Publication title -
rare tumors
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.285
H-Index - 15
eISSN - 2036-3613
pISSN - 2036-3605
DOI - 10.4081/rt.2014.5404
Subject(s) - medicine , radiation therapy , external beam radiotherapy , adjuvant radiotherapy , ependymoma , metastasis , surgery , lesion , adjuvant chemotherapy , radiology , cancer , brachytherapy , breast cancer
Myxopapillary ependymoma (MPE) is a World Health Organization grade I ependymoma that is quite rare and generally thought to be benign. Possible drop metastasis from MPE has been reported three times in the literature; in each case there were cotemporaneous additional MPE lesions. We report the case of a man who had a piecemeal gross total resection of a MPE at L1-L3 followed by adjuvant external beam radiotherapy (EBRT) who presented sixteen months later with a lesion in the thecal sac consistent with drop metastasis. A subtotal resection and adjuvant EBRT were performed. The patient has been disease-free in follow-up 27 months from the second surgery. A review of the literature regarding the treatment for MPE showed that gross total resection is optimal initial management. Several retrospective studies supported the role of adjuvant radiotherapy in enhancing local control and progression-free survival. Chemotherapy has a minimal role in the management of MPE
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom